Type 2 Diabetes Clinical Trial
Official title:
Intermittent Fasting for Metabolic Health, Does Meal Timing Matter?
Obesity is a serious medical condition, the adverse consequences of which include increased risk of cardiovascular disease, diabetes mellitus, reduced fertility and cancer. The economic cost of obesity was placed at $58 billion dollars in Australia in 2008. Studies in mice and non-human primates have shown that moderate caloric restriction (CR) increases lifespan and reduces the incidence of cardiovascular disease, cancer, and type 2 diabetes. Reduced risk of chronic diseases is also observed in humans following CR. However, daily CR is difficult to maintain long term, since the body defends against weight loss by inducing "metabolic adaptation" and altering the hormonal appetite response. An emerging number of studies are examining the effects of limiting food intake to prescribed time periods per day, or every other day. Intermittent, or time restricted feeding describes a dieting approach where food is available ad libitum, however only for a limited period of time (i.e. 3-12 hours). This study will examine the effects of fasting for 15h/day and eating for 9-h per day on glycemic control and metabolic health. This study will build on the existing knowledge base in humans as to whether meal timing, rather than caloric restriction per se, is important to provide the stimulus required to improve metabolic health and reduce risk of chronic disease. Moreover, it will examine whether restricting feeding to later in the day is of lesser benefit to health.
The timing of meal intakes distributed across the wake cycle may play a role in body weight
regulation and metabolic health in humans. However, only a limited number of studies have
interrogated this in humans. Epidemiological evidence shows that individuals who report
consuming more of their daily energy intake at the evening meal were more overweight, than
those who reported consumed more of their energy intake before lunch. Similarly, eating lunch
late in the day (after 15:00 hrs) was predictive of poorer weight loss during a 20-week
dietary intervention study and individuals randomized to consume more calories at breakfast
had greater weight loss versus those randomized to eat more calories at dinner after 12
weeks. Taken together these data suggest that consuming more calories in the morning may be
beneficial for weight management.
Randomised controlled cross-over intervention, where lean individuals were instructed either
to consume all of their calories required for weight maintenance over a 4 hour period from
1700-2100h, or as 3 meals/d for 8 weeks. Significant reductions in body weight and body fat
mass, by 1.4 and 2.1 kg respectively, were noted when following the TRF protocol. Consumption
of the evening meal was supervised within the laboratory, to ensure subjects consumed the
entire meal. In light of evidence that rats switched from a nibbling diet to 1 meal/d
increased gluconeogenesis and free fatty acid flux from fat depots, the authors postulated
that the greater weight loss may be associated with changes in metabolism. Despite this small
amount of weight loss, fasting blood glucose levels were increased, and TRF resulted in
poorer glucose tolerance in response to an oral glucose tolerance test (OGTT). Thus,
consuming a single, large "dinner" meal was detrimental for metabolic health, although no
differences in insulinemia were noted. It is unclear whether responses may have differed if
the food allowance was prescribed at breakfast or lunch times. Just one other study has
performed a randomised controlled TRF protocol in humans. In this study, healthy, lean male
subjects were allowed to eat ad libitum for 13h per day (6am-7pm) for 2 weeks. Participants
reported eating significantly less on the TRF versus the control condition, and lost -0.4kg
compared with a gain of +0.6kg in the control condition. Whilst this is a minor change in
body weight, this pattern is not that atypical of modern eating patterns, and further
restriction of eating times, and assessment of obese individuals under these conditions is
warranted. The metabolic health impacts were not reported in that study.
Several studies in animals have shown that, when fed in the "wrong" phase (i.e. eating when
the animal would normally rest) the mice become obese, despite similar energy intake and
expenditure, suggesting that the timing of food intake is important in driving the obese
phenotype. Moreover, when high-fat energy intake is restricted to the active phase, the
animals become obese, but do not develop the metabolic sequelae that are observed when the
same foods are provided in the inactive phase. In humans, shift workers are at higher risks
of metabolic disorders, including obesity and type 2 diabetes, possibly as a result of clock
desynchronization. Alternatively, this may be the result of mis-timing of meals. For example,
epidemiological evidence suggests that a shift toward consuming more calories at night is
more likely to result in being overweight when compared with breakfast eaters, while eating a
greater proportion of calories at the dinner meal is associated with a higher overall intake
and an increased risk for obesity, metabolic syndrome and non-alcoholic fatty liver disease.
When 10 healthy adults were subjected to a 28 hour "day" during which they consumed 4
isocaloric meals, the resulting circadian misalignment was associated with increased blood
glucose, even in the presence of increased insulin. Moreover, in 3 of the subjects, a
postprandial glucose response was observed that would suggest a pre-diabetic state. Under
these circumstances, it appears that consuming calories at "night" in humans may have
deleterious effects on health, and suggests that meal timing may play a key role in
mitigating the metabolic impairment that occurs when the circadian rhythm is disrupted. To
further confuse the matter, among breakfast skippers, a higher eating frequency (i.e. ≥ 4
eating occasions per day) has been shown to be associated with a higher risk for type 2
diabetes, compared with breakfast eaters who consumed 1-3 meals per day. In light of this
evidence, and the apparent beneficial effects of TRF on metabolic health, the importance of
the morning meal and its synchronisation with circadian rhythms is unclear.
Screening (S) - Participants will attend the South Australian Health and Medical Research
Institute (SAHMRI) and have the research protocol explained to them in detail. Informed
consent to participate in the study, including a verbal indication that they understand the
general study protocol and requirements is then obtained. Participants will be assessed by a
screening questionnaire for diet, medical, and exercise history to determine their
eligibility according to the above criteria. Routine clinical checks are then performed
(weight, height, waist circumference, blood pressure). If subjects meet eligibility criteria,
they will be invited to take part in the study. Participants will have a dual energy x-ray
absorptiometry scan and be fitted with a continuous glucose monitor for one week. During this
time, participants will also wear an accelerometer and complete diet diaries to complete a
baseline assessment of meal intake pattern. Participants will then be randomly assigned to
undergo one of two study arms (TRF-b and TRF-d) for one week each. Conditions are separated
by a 2-week washout period, during which participants will be encouraged to maintain their
usual dietary pattern and physical activity levels.
Metabolic Testing (D0, D7) during each study condition: Participants arrive at 0700 following
an overnight fast. Weight and blood pressure is measured following a seated 10 min rest. A 20
G cannula is inserted into an antecubital vein. A fasting blood sample is drawn for lipids,
cytokines and glucoregulatory hormones. Resting metabolic rate and whole body nutrient
oxidation is measured via indirect calorimetry. A second fasting blood sample is taken
immediately prior to a standard test meal at 0800am or 1200pm, depending on study condition
and gastric emptying, postprandial glucoregulatory and gut hormone response to re-feeding
will be tested for 3 hours. At the first metabolic visit of each study condition,
participants will be fitted with the continuous glucose monitor (CGM), and follow their
assigned TRF protocol and assessments by CGM will continue for 7 days, before returning for
the D7 metabolic visit. Diet records will be taken and accelerometers worn on the upper arm
for each period during the study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |